Draft Medical Policies BlueCross BlueShield of Tennessee

BlueCross BlueShield of Tennessee works to ensure that Medical Policies are developed in an open, collaborative manner with our providers. We invite you to submit comments during the development phase of our Medical Policies.

Medical policies are developed using an evidence-based evaluation process. The medical evidence used in this process comes from several sources, including independent medical technology review organizations, the peer reviewed medical literature, and expert opinions from BCBST network specialists. We especially welcome comments that include this type of information. All Medical Policies are reviewed and approved by a panel of BCBST Medical Directors as well as board certified network physicians before final adoption by the company.

Policy	Policy Name	Date Posted	Date Removed
DMP0825-20	Nipocalimab-aahu (Imaavy™)	08/19/25	09/19/25
DMP0825-21	Human Amniotic Membrane Grafts and Amniotic Fluid Injections	08/21/25	09/21/25
DMP0825-22	Abatacept (Orencia®)	08/25/25	09/25/25
DMP0825-23	Certolizumab Pegol (Cimzia®)	08/25/25	09/25/25
DMP0825-24	Leuprolide Acetate Depot Suspension	08/25/25	09/25/25
DMP0825-25	Leuprolide Suspension	08/25/25	09/25/25
DMP0825-26	Goserelin Acetate (Zoladex®)	08/25/25	09/25/25
DMP0825-27	Infliximab Products	08/25/25	09/25/25
DMP0825-28	Leuprolide acetate (Eligard®, Vabrinty™)	08/25/25	09/25/25
DMP0825-29	Triptorelin Pamoate (Trelstar®)	08/25/25	09/25/25
DMP0925-01	Daratumumab (Darzalex®)	09/08/25	10/08/25
DMP0925-02	Daratumumab and hyaluronidase-fihj (Darzalex Faspro®)	09/08/25	10/08/25
DMP0925-03	Ipilimumab (Yervoy®)	09/08/25	10/08/25
DMP0925-04	Pegaspargase (Oncaspar®)	09/08/25	10/08/25
DMP0925-05	Pemetrexed (Alimta®; Pemfexy™, Pemetrexed™, Pemrydi RTU, Axtle™)	09/08/25	10/08/25
DMP0925-06	Ramucirumab (Cyramza®)	09/08/25	10/08/25
DMP0925-07	Alpha-1 Proteinase Inhibitor (Aralast NP®, Glassia®, Prolastin-C®, Zemaira®)	09/08/25	10/08/25
DMP0925-08	Avelumab (Bavencio®)	09/08/25	10/08/25
DMP0925-09	Bevacizumab Products	09/08/25	10/08/25
DMP0925-10	Efbemalenograstim alfa-vuxw (Ryzneuta®)	09/08/25	10/08/25
DMP0925-11	Nivolumab (Opdivo®)	09/08/25	10/08/25
DMP0925-12	Mepolizumab (Nucala®)	09/08/25	10/08/25
DMP0925-13	Omalizumab Products: Omalizumab (Xolair®); Omalizumab-igec (Omlyclo®)	09/08/25	10/08/25
DMP0925-14	Tocilizumab (Actemra®); Tocilizumab-anoh (Avtozma®); Tocilizumab-bavi (Tofidence™); Tocilizumab-aazg (Tyenne®), tocilizumab-aazg, tocilizumab-anoh	09/08/25	10/08/25
DMP0925-15	Ustekinumab Products	09/08/25	10/08/25
DMP0925-16	Vertebral Fracture Assessment with Densitometry or Biomechanical Computed Tomography	09/15/25	10/15/25

 

Pharmacy Policy Comments:

Please reference the policy name or tracking number in your comments.
To submit comments about the draft Pharmacy Policies:
Click the “Pharmacy Policy Comments” above or click here: Comments or Feedback.

Medical Policy Comments:

Please reference the policy name or tracking number in your comments.
To submit comments about the draft Medical Policies:
Click the “Medical Policy Comments” above or click here: Comments or Feedback.

Comments can also be mailed to:

BlueCross BlueShield of Tennessee
Medical Policy
1 Cameron Hill Circle
Chattanooga, TN 37402